Seeking participants for a new liver cancer study

This study is comparing the study drug, Pexa-Vec, followed by Sorafenib versus Sorafenib (standard treatment) in patients with advanced liver cancer without prior medication treatment

The main purpose of this study is to find out whether the study drug Pexa-Vec followed by standard Sorafenib treatment is better at treating your cancer than standard Sorafenib treatment alone.  

Pexa-Vec is a virus that has been altered in a laboratory (genetically modified) to infect and destroy cancer cells and release a protein called GM-CSF that plays a role in the defense system fighting cancer.

Anticipated date that enrolment will close: December 2020

Who can take part

  • People with a diagnosis of liver cancer

What is involved for you

  • medical history
  • physical exam
  • electrocardiogram (ECG)
  • weight, height, blood pressure, pulse, heart rate
  • liver ultrasound
  • CT scan
  • medication injection
  • blood samples
  • urine samples
  • health questionnaires
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2015.221
Nicola Dalgliesh
03 9342 8995
Zafirah Khan
03 9342 8995